Cao, J.; Li, S.; Li, D.; Hua, W.; Guo, L.; Xia, Z.
Development and Validation of Pretreatment Serum Total Bilirubin as a Biomarker to Predict the Clinical Outcomes in Primary Central Nervous System Lymphoma: A Multicenter Cohort Study. Cancers 2023, 15, 4584.
https://doi.org/10.3390/cancers15184584
AMA Style
Cao J, Li S, Li D, Hua W, Guo L, Xia Z.
Development and Validation of Pretreatment Serum Total Bilirubin as a Biomarker to Predict the Clinical Outcomes in Primary Central Nervous System Lymphoma: A Multicenter Cohort Study. Cancers. 2023; 15(18):4584.
https://doi.org/10.3390/cancers15184584
Chicago/Turabian Style
Cao, Jiazhen, Shengjie Li, Danhui Li, Wei Hua, Lin Guo, and Zuguang Xia.
2023. "Development and Validation of Pretreatment Serum Total Bilirubin as a Biomarker to Predict the Clinical Outcomes in Primary Central Nervous System Lymphoma: A Multicenter Cohort Study" Cancers 15, no. 18: 4584.
https://doi.org/10.3390/cancers15184584
APA Style
Cao, J., Li, S., Li, D., Hua, W., Guo, L., & Xia, Z.
(2023). Development and Validation of Pretreatment Serum Total Bilirubin as a Biomarker to Predict the Clinical Outcomes in Primary Central Nervous System Lymphoma: A Multicenter Cohort Study. Cancers, 15(18), 4584.
https://doi.org/10.3390/cancers15184584